ライフサイエンスコーパス: disease duration

1 sures (pain severity, upper limb disability, disease duration).

2 n serum correlated with disease severity and disease duration.

3 Panuveitis was associated with longer disease duration.

4 her pathologic variables are associated with disease duration.

5 in comparison to controls and increased with disease duration.

6 experience smaller disease burden and longer disease duration.

7 efficiency was significantly correlated with disease duration.

8 t disease severity and is independent of the disease duration.

9 Disease severity increased with disease duration.

10 tion of regional and total brain scores with disease duration.

11 ymptoms and signs, rates of progression, and disease duration.

12 patients and weaker in patients with longer disease duration.

13 easurements and pulmonary function tests and disease duration.

14 f early active plaques rapidly declined with disease duration.

15 ecline of clinical outcome measures based on disease duration.

16 effect of TREM2 genotype on age at onset and disease duration.

17 s of retinal atrophy, decline in vision, and disease duration.

18 entral macular thickness, visual acuity, and disease duration.

19 nent cerebellar signs, which were related to disease duration.

20 ly in the inner layers of patients with long disease duration.

21 ndent from age, sex, biological markers, and disease duration.

22 ity as measured by several rating scales and disease duration.

23 cted in Parkinson disease patients with long disease duration.

24 area, number of SC T2 lesions, age, sex, and disease duration.

25 fy biomarker panels that could predict total disease duration.

26 -nitrotyrosine, both of which increased with disease duration.

27 out of STN DBS effects varies with Parkinson disease duration.

28 s in the NAWM of MS patients with increasing disease duration.

29 parkin-mutation carriers (<3%), despite long disease duration.

30 f controls as well as in patients with short disease duration.

31 nt, and increased survival without modifying disease duration.

32 idual VRF on DF and JCL, considering age and disease duration.

33 xhibited correlations with anxiety level and disease duration.

34 ration, age at Parkinson's disease onset and disease duration.

35 ODI and ISO correlated with disease duration.

36 tive impairment, after adjusting for age and disease duration.

37 adjusting atopy status, smoking history, and disease duration.

38 aggressive disease course, rather than long disease duration.

39 memory and psychomotor speed correlated with disease duration.

40 , Expanded Disability Status Scale score and disease duration.

41 significantly associated with differences in disease duration.

42 complex profiles were associated with longer disease duration.

43 al group and patients with bvFTD had similar disease durations.

44 may not apply to populations with different disease durations.

45 ion of patients with low EDSS scores at long disease durations.

46 ancreata across a wide range of ages and T1D disease durations.

47 patients with relapsing-remitting MS (median disease duration, 0.8 year) were analyzed by using the s

48 signed (mean age, 62 years [SD, 9]; 68% men; disease duration, 0.9 year [SD, 0.7]; mean UPDRS part I

49 s disease (11 females, age 57 +/- 9.1 years, disease duration 13.3 +/- 6.3 years) who received bilate

50 ng-remitting multiple sclerosis (>/= 4 years disease duration), 13 subjects with secondary progressiv

51 d 264 MS patients (mean age 46.9+/-10 years, disease duration 14.6+/-10 years; 67.8% relapsing-remitt

52 e at diagnosis, 63.9 [10.3] years; mean [SD] disease duration, 14.6 [7.7] years) were studied.

53 omen; monthly attack frequency: 3.2 +/- 2.5; disease duration: 14 +/- 8.4 years) and 115 matched heal

54 le, 625 female), mean age 49 years with mean disease duration 17 years.

55 ndrome/early multiple sclerosis (</= 3 years disease duration), 18 subjects with relapsing-remitting

56 29 subjects with mild-to-moderate PD (median disease duration = 2.3+/-1.9 years) and 18 healthy match

57 Patients with somatic mutations had a longer disease duration (37 vs 8 months, P < .04), and shorter

58 ve patients with probable AD and matched for disease duration (45 German-Italian bilingual speakers a

59 Inclusion criteria were age 48-65 years, disease duration 5 years or longer, motor fluctuations,

60 62 +/- 7 years; education = 16 +/- 3 years; disease duration = 5.8 +/- 3.9 years) and 27 controls (a

61 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted i

62 female; mean age at death 64.7 years; median disease duration 6.5 years, range 2.2 to 15.6 years).

63 men and 160 men (mean age = 43 years, median disease duration = 6 years, median EDSS = 1.5 [range = 0

64 (23 men and 7 women; mean age, 66 +/- 6.2 y; disease duration, 6.4 +/- 4.0 y; Hoehn and Yahr stage, 2

65 of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls.

66 s disease (mean age 63.8 years +/- 6.8; mean disease duration 9.4 years +/- 2.5) both OFF and ON levo

67 and 41% of that with SARA were explained by disease duration, age at onset and the shorter abnormal

68 e compulsive behaviours matched by age, sex, disease duration, age at Parkinson's disease onset and d

69 n ARRP participants (P < .001, adjusting for disease duration, age of enrollment).

70 sion analysis, choroidal thickness, age, and disease duration (all P < 0.01) all were significant pre

71 A correlation between radial diffusivity and disease duration along the corticospinal tracts (r = 0.8

72 ittle is known about which factors influence disease duration among patients with DLB.

73 r monogenic dystonias, adjusting for age and disease duration and (iii) weighted linear regression an

74 tients needed walking aids after 10 years of disease duration and a quarter were wheelchair dependent

75 mutation except for an indication of longer disease duration and age in patients with highest mutati

76 elated to aura and WMHs (P < .01) but not to disease duration and attack frequency.

77 eduction was positively associated with both disease duration and cumulative oral steroid dose.

78 pathology on MRI correlated positively with disease duration and functional impairment.

79 ts with type 2 diabetes is dependent on both disease duration and glycaemic control.

80 ortem neuroimaging, directly correlated with disease duration and inversely correlated with brain wei

81 PBV/PAenh correlates with disease duration and inversely correlates with RVD.

82 form patients and caregivers of the expected disease duration and may help with care planning.

83 disability outcomes, with trends for longer disease duration and older age at first treatment.

84 come (at P < 0.05), with preset variables of disease duration and original treatment assignment.

85 ns, which showed a negative correlation with disease duration and overlapped with striatal regions sh

86 ayer thickness was inversely correlated with disease duration and Parkinson disease severity, and was

87 more likely among obese females with longer disease duration and poor glycemic control.

88 Given the short disease duration and predominant dystonic phenotype, the

89 Baseline variables including age, disease duration and relapse rate were compared in univa

90 Correlation with disease duration and severity highlights the need for ra

91 oretinography (ERG) and correlate the ERG to disease duration and severity of inflammation.

92 Adjusted for age, sex, disease duration and smoking history, pRBD was associate

93 and degree of SI on DWI that correlates with disease duration and the degree of spongiosis.

94 significant correlation was observed between disease duration and the Expanded Disability Status Scal

95 sability (Expanded Disability Status Score), disease duration and time on treatment.

96 s was examined adjusting for age, sex, race, disease duration and treatment status.

97 th diabetes mellitus (especially with longer disease duration) and hyperlipidemia or obesity were ass

98 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generat

99 The generational effect on age at onset, disease duration, and age at death was estimated using a

100 Generational effect on age at onset, disease duration, and age at death.

101 for age, sex, randomized treatment, region, disease duration, and baseline EDSS score.

102 Data concerning demographics, age at onset, disease duration, and clinical and pathological features

103 significantly lower tryptase levels, shorter disease duration, and earlier disease onset.

104 t Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examinatio

105 maternal education, seizure disorder, kidney disease duration, and genetically defined ancestry.

106 Randomization was balanced for age, sex, disease duration, and glutamic acid decarboxylase autoan

107 ith pain had an earlier age of onset, longer disease duration, and higher depression and motor severi

108 oss used a linear mixed model with sex, age, disease duration, and HLA-DRB1*15:01 as covariates.

109 to evaluate the influence of baseline BCVA, disease duration, and ischemia on BCVA outcomes at month

110 lumes, adjusting for the patients' sex, age, disease duration, and lesion volume.

111 CM and were correlated to corneal sensation, disease duration, and number of recurrences.

112 on) were correlated, adjusting for age, sex, disease duration, and optic neuritis (ON) history.

113 on functional class, 6-minute walk distance, disease duration, and red cell distribution width also p

114 0.001; p < 0.0001 after correcting for age, disease duration, and sex).

115 In baseline analyses adjusted for age, disease duration, and sex, for every 0.2 lower LTL, EDSS

116 adjustment for age, sex, years of education, disease duration, and site.

117 phy was correlated with clinical disability, disease duration, and, to a lesser extent, conventional

118 lzheimer's disease with distinctly different disease durations, and correlated the data with APOE gen

119 dex, Expanded Disability Status Scale score, disease duration, annual relapse rate, and treatment sta

120 ssion analyses that included gender, age and disease duration as covariates.

121 , 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than thos

122 analyses of event-free survival according to disease duration at screening.

123 Age at baseline MRI, disease duration, atrophy, codon 129 methionine valine p

124 analysis adjusted by sex, age at onset, and disease duration attributed to GBA carriers a greater ri

125 bjects (n = 12) with approximately 30 years, disease duration before and 6 months after intrahepatic

126 PBV/PAenh correlated with disease duration (beta = 0.13, p = 0.04), and inversely

127 fferences in age at onset, age at death, and disease duration between genetic groups and individual m

128 Multiple regression analysis revealed disease duration, but not age, gender or skin involvemen

129 were correlated with severity of disease and disease duration by Spearman correlation.

130 version recovery lesion loads, age, sex, and disease duration), cervical cord GM areas had the strong

131 31.4 +/- 9.0; RRMS: 33.0 +/- 8.7 years; mean disease duration: CIS: 7.2 +/- 15 months; RRMS: 8.0 +/-

132 Disease duration, clinical course, age, and gender contr

133 ya disease and estimate its burden regarding disease duration, clinical presentation, and impact on q

134 1, 2011, and Nov 3, 2016, 244 patients (mean disease duration: clinical management group, 0.9 years [

135 independent cohorts (72 patients with short disease duration [cohort 1] and 240 patients with longer

136 tion [cohort 1] and 240 patients with longer disease duration [cohort 2]) treated at a single German

137 neocortical) LBD was associated with shorter disease duration compared with transitional LBD (beta, -

138 Diffuse LBD was associated with shorter disease duration compared with transitional LBD, and thi

139 ANG-ALS, we assembled all clinical onset and disease duration data and determined if these were corre

140 Total disease duration, defined as the time from symptom onset

141 ds models that included OCT metrics and age, disease duration, disability, presence of previous unila

142 There was no relationship of PHOMS with age, disease duration, disease course, disability, or disease

143 Disease duration, disease-free duration, previous inject

144 logistic regression, adjusting for sex, age, disease duration, duration of follow-up, years of educat

145 n in the nonglomerular group was congenital, disease duration equated with age.

146 d slower washout, while patients with longer disease duration experienced faster washout.

147 d to disease duration: patients with shorter disease duration experienced slower washout, while patie

148 cinosis is positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibo

149 Mean disease duration for all SOD1 was 4.6+/-6.0 and 1.4+/-0.

150 attack (54 months) was similar to the median disease duration for AQP4-IgG-positive patients with rLE

151 a on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations

152 Shorter disease duration from cognitive symptom onset to death w

153 Median disease duration from symptom onset to death was 7.51 ye

154 tients with Parkinson's disease at different disease durations from time of diagnosis.

155 vailable on sex, age at motor symptom onset, disease duration (from motor symptom onset to death or t

156 pathic cardiomyopathy (0.4 [0.2-1]), cardiac disease duration greater than 2 years pre-extracorporeal

157 patients with MS of long-standing duration (disease duration >/= 10 years) and in 60 healthy control

158 igible patients (ie, those aged 18-75 years, disease duration >/=3 years, Toronto Western Spasmodic T

159 neurysm was 4.2-fold higher in patients with disease duration >5 years (p = 0.042, OR = 4.237, 95% CI

160 ely in patients with infected necrosis or NP disease duration >=6 months.

161 ndividuals with unlimited walking ability at disease durations >15 years.

162 Patients with a shorter disease duration had higher frequencies of insulin-react

163 ly those with a short diagnostic latency and disease duration, had higher plasma NfH levels at an ear

164 oratory data of diabetic patients, including disease duration, haemoglobin A1c (HbA1c) levels and uri

165 hazards analyses adjusting for age, sex, and disease duration (hazard ratio [HR] 2.27 [95% CI 1.04-5.

166 hey did differ significantly with respect to disease duration; hemoglobin level; frequency of thrombo

167 The extent of reduction correlated with disease duration in all subjects with epilepsy.

168 t; (ii) a correlation between IL6 levels and disease duration in carriers of PRKN/PINK1 mutations, wh

169 d affect (anxiety) in both groups as well as disease duration in CDs.

170 clinical parameters such as focus score and disease duration in human patients.

171 y of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, M

172 Since OSA disease duration in our subjects is unknown, these findi

173 To identify pathologic correlates of disease duration in participants with Lewy body disease

174 never) and surgery in IBD, and incorporated disease duration in the analysis.

175 IGF1 levels significantly decreased with disease duration, in parallel with declining beta-cell f

176 Surprisingly, disease duration is independent of the mutation's length

177 ugh disease onset and mortality are delayed, disease duration is not affected.

178 Models were adjusted for age, education, disease duration, language, and levodopa equivalent dail

179 phic data, smoking status, age at diagnosis, disease duration, location, and behaviour, previous medi

180 six early stage multiple sclerosis subjects (disease duration </=5 years) and 24 age-matched healthy

181 was tested in a subgroup of PD patients with disease duration <=2 years (PDE).

182 yes or no), weight (<70 kg or >/=70 kg), and disease duration (</=2 years or >2 years) after 8 weeks

183 Disease duration, lymphocyte count, and azathioprine use

184 Disease duration-matched BCVA was investigated in 12 of

185 chronic disease phase and 65 age-, sex-, and disease duration-matched multiple sclerosis patients.

186 ment for levodopa equivalent dose, sex, age, disease duration, MDS-UPDRS III score at the first asses

187 R47H carriers demonstrated a shortened disease duration (mean [SD], 6.7 [2.8] vs 11.1 [6.6] yea

188 medications at baseline had longer diabetes disease duration (mean, 17.4 and 20.9 years, respectivel

189 ed as semantic dementia, and they had longer disease duration (mean: 15.3 years) compared with the ot

190 ith vs those without calcinosis had a longer disease duration (median, 6.9 years; range, 2.4-18.1; vs

191 .0 years [IQR, 26.3-38.3 years]), with short disease durations (median, 1.0 months [IQR, 1.0-2.0 mont

192 0 years]) consisting of patients with longer disease durations (median, 36.0 months [IQR, 21.0-60.0 m

193 Data regarding disease duration, medications, complications, recent blo

194 5 +/- 7.4 years old; 6.0 +/- 4.2 years motor disease duration; modified Hoehn and Yahr mean stage 2.4

195 e, younger, younger at PD onset, have longer disease duration, more severe non-motor symptoms (includ

196 Neither disease duration nor cumulative oral or intravenous ster

197 sociated with the primary outcome were short disease duration (odds ratio [OR] 0.64, 95% CI 0.41-0.99

198 ubjects and 30 PD patients at early stage of disease (duration of disease </= 5 y) with mild and unil

199 Of 1049 patients with disease duration of >15 years, 200 (19.1%) had most rece

200 <1 year (group A [n = 80]) and those with a disease duration of >5 years (group B [n = 120]) were in

201 Somatic mutations in AA patients with a disease duration of >6 months were associated with a 40%

202 s (n = 200) with noninfectious uveitis and a disease duration of <1 year (group A [n = 80]) and those

203 observed in tissues from younger donors with disease duration of <10 years.

204 et of 15.3 years (range, 3-28 years), a mean disease duration of 12.1 years, and a mean age at baseli

205 Additional eligibility criteria included disease duration of 2-10 years and objective evidence of

206 hort of 61 patients with T1D with an average disease duration of 21 years with 54 well-matched contro

207 e ability to walk independently for a median disease duration of 22 years.

208 ability to walk independently after a median disease duration of 23 years and became wheelchair depen

209 age of 34.4 (range, 28-39) years and a mean disease duration of 28.8 years.

210 At baseline, patients had median disease duration of 3.2 years, median ELF score of 9.8,

211 stribution was decreased by 33% after median disease duration of 4.7 years (0.5-12.4 years).

212 an age, 76.7 years; 93.5% men) with a median disease duration of 55.6 months and mild to moderate hea

213 The mean disease duration of all patients was 15.0 +/- 13.4 mo at

214 xicity and seeding that were correlated with disease duration of FTLD subjects.

215 ernational panel criteria for diagnosis with disease duration of less than 15 years were eligible.

216 ized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if t

217 vere underweight, severe acute malnutrition, disease duration of more than 21 days, and referral from

218 and between Parkinson disease patients with disease durations of less than or at least 10 years.

219 lysis to estimate the effect of age, sex and disease duration on GPi DBS outcomes.

220 mixed-effects models adjusting for age, sex, disease duration, optic neuritis and genetic ancestry an

221 Parents whose child had longer disease duration or a severe reaction and parents who we

222 No generational effect was observed for disease duration or age at death.

223 led to show a benefit in patients with short disease duration or an increased level of C-reactive pro

224 p = 0.006), but there were no differences in disease duration or disability.

225 (%CCR9) in SPMS did not correlate with age, disease duration or expanded disability status scale sco

226 f glucocorticoids (weak evidence) but not to disease duration or severity/activity, gender, age, or A

227 pathogenic coding variants did not influence disease duration or site of onset.

228 g the SP phase increased proportionally with disease duration (OR=1.07 for each additional year; p<0.

229 etween GABA responses, demographic features, disease duration, or disease severity in the whole popul

230 exponentially at a rate of 5.4% per year of disease duration (P < .001, 95% CI 3.7-7.1).

231 exponentially at a rate of 7.3% per year of disease duration (P < .001, 95% CI 5.4-9.1), and ellipso

232 exponentially at a rate of 8.1% per year of disease duration (P < .001, 95% confidence interval [CI]

233 halamus and brainstem correlated with longer disease duration (P < 0.05) and higher disease burden sc

234 ereas only the cervical cord correlated with disease duration (p < 0.05).

235 ders had lower endoscopy scores during their disease duration (P = .013).

236 resent in younger individuals with a shorter disease duration (P = .02).

237 nzymatic activity was associated with longer disease duration (P = 0.002) in adjusted models, suggest

238 n severity was significantly associated with disease duration (P = 0.02), and COMT rs6267 T allele (P

239 e HCVA (p = 0.02) and worse LCVA per year of disease duration (p = 0.039).

240 5 <5 x 109/L) and was associated with longer disease duration (P = 7 x 10-6), lower nadir platelet co

241 Physical scores increased with age and disease duration (p<0.001, p<0.001), but there was a wea

242 ohort, eotaxin-1 (CCL11) was associated with disease duration particularly in patients who had second

243 Despite similar age and disease duration, patients with the diffuse/malignant ph

244 , and this variation was strongly related to disease duration: patients with shorter disease duration

245 cts were matched first for age at death then disease duration (PD only) for comparison.

246 founding factors of sexual dysfunction: age; disease duration; physical disability; depression; bladd

247 ic head MRI scans spanning 1.0-16.8 years of disease duration prior to death were analysed.

248 regression adjusted for age, calendar year, disease duration, propensity scores, and use of other IB

249 l variability, which was not associated with disease duration (R (2) = 0.1, p > 0.2), did correlate w

250 0.6) at follow-up (P = .001) correlated with disease duration (r = 0.47, P = .003 at baseline and r =

251 e choriocapillaris and the Sattler layer and disease duration (R2 = 0.98 and R2 = 0.99, respectively;

252 e hippocampus and parahippocampus revealed a disease duration-related increase in neuronal cytoplasmi

253 ree of atrophy (rho = -0.585, p = 0.011) and disease duration (rho = 0.632, p = 0.005) in the anterom

254 found between the (11)C-donepezil signal and disease duration, severity of constipation, gastric empt

255 After adjusting for disease duration, severity of corticospinal tract degene

256 After correcting for age, disease duration, sex, and T2 lesion volume, the total (

257 remaining insulin-containing islets and long disease duration show elevated levels of CD8 T cells in

258 multivariate model adjusted for age, gender, disease duration, smoking status, vitamin D levels, body

259 r performance than did noncarriers with long disease duration, suggesting slower disease progression.

260 dementia with Lewy bodies (DLB) have shorter disease duration than patients with Alzheimer disease de

261 the lower extremities, which correlates with disease duration (thigh fat fraction R(2) = 0.35, p = 0.

262 After conditioning on autoantibody and disease duration, time-averaged DAS28 showed significant

263 PD-ICB were matched for age, gender and disease duration to 42 patients with PD without ICB over

264 ontrols only in patients with ALS with short disease duration to baseline sampling.

265 ng were more likely than those with a longer disease duration to benefit from nusinersen.

266 The objective of this study was to document disease duration, treatment history, and disease activit

267 anded Disability Status Scale (EDSS) scores, disease duration, treatments, prior optic neuritis episo

268 Disease duration, Unified Parkinson's Disease Rating Sca

269 ificantly exponential correlations to stage; disease duration; Unified Parkinson Disease Rating Scale

270 body levels and influenza viral shedding and disease duration using accelerated failure time models.

271 Multivariable models for total disease duration using biomarkers from plasma, CSF, and

272 Disease duration varied but similar stories emerged abou

273 years (SD 9.3), 63.5% were men and the mean disease duration was 1.3 years (SD 0.9).

274 Median age was 60 years (IQR 57-65), disease duration was 11 years (6-25), and DAS28 score wa

275 The median disease duration was 17 years.

276 Median age was 65 years, and median disease duration was 5.2 years.

277 Mean disease duration was 6.4 years (SD 4.9) in the C9orf72 g

278 Mean disease duration was 9.8 years (range: 1.2-32.7 years).

279 ) age was 39.5 (11.2) years and preoperative disease duration was 97.9 (85.8) months; 83 patients (91

280 s. 270.05+/-24.6 mum; P = 0.04), and greater disease duration was associated with decreases in retina

281 A small, dose-dependent decrease in disease duration was found in CLR01-treated mice, relati

282 Disease duration was matched to investigate differences

283 In contrast, such a correlation with disease duration was not found in patients with cognitiv

284 een onset of motor and dementia symptoms and disease duration was shorter (p<0.0001 for all compariso

285 Disease duration was significantly inversely correlated

286 With longer disease duration, we found an additional, progressive ac

287 Mean age and disease duration were 35.1 and 0.85 years, respectively,

288 Earlier age of seizure onset and longer disease duration were associated with a greater extent o

289 at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n = 1234).

290 On multivariate analysis, HGD, DALM, and disease duration were independent risk factors for posto

291 ilability at rest positively correlated with disease duration were lateral and non-overlapping with s

292 with CMTNSv2, SF-36v2-physical component and disease duration were MRI determined calf intramuscular

293 Lithium medication, later onset and short disease duration were related to higher FA along multipl

294 Fingertip ulcers and disease duration were strongly associated with calcinosi

295 acuity, central macular thickness (CMT), and disease duration were the main outcomes.

296 aring white matter (NAWM) corresponding with disease duration, when corrected for age.

297 ctions were greater in patients with shorter disease duration, which suggests a potential benefit of

298 ma tACS on single-pulse MEPs correlated with disease duration, while changes in SICI correlated with

299 nresponders spent 54% and 97% of their total disease duration with active EoE (P < .001) and 23% and

300 gan donors with type 1 diabetes with a short disease duration with high-risk HLA genes using a direct